Lixte Biotechnology Holdings Inc (LIXT NASDAQ) stock market data APIs
$5.6029
-0.11(-2%)
as of September 17, 2025
Try our APIs with
free plan!
Lixte Biotechnology Holdings Inc Financial Data Overview
Price chart is built with
Anychart
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Prev. Close
5.6029
Open
5.4921
High
5.8324
Low
5.4921
52 wk Range
0.64-6.26
Market Cap
25 680 K
Shares Outstanding
4 561 K
EPS
-0.29
Beta
0.477
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lixte Biotechnology Holdings Inc data using free add-ons & libraries
Get Lixte Biotechnology Holdings Inc Fundamental Data
Lixte Biotechnology Holdings Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lixte Biotechnology Holdings Inc News
New
After-Hours Biotech Gainers: Insider Buys, Trial Updates, And Strategic Deals Fuel Momentum
(RTTNews) - Biotech stocks are showing renewed momentum, with several small-cap names posting notable after-hours gains and attracting investor attention. From insider buying and strategic partnership...
LIXTE Biotechnology makes $2.6M initial purchase of digital currency
* LIXTE Biotechnology (NASDAQ:LIXT [https://seekingalpha.com/symbol/LIXT]) said on Wednesday that it has made an initial purchase of cryptocurrencies [https://seekingalpha.com/pr/20228805-lixte-biot...
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today an...
Lixte Biotechnology appoints new CFO and board members
* Lixte Biotechnology (NASDAQ:LIXT [https://seekingalpha.com/symbol/LIXT]) appointed Peter Stazzone as chief financial officer. * Lourdes Felix and Guy Primus joined LIXTE’s board of directors. ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
